Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05613608 · ClinicalTrials.gov registry record · Phase 2

Alcohol Use Disorder and Cannabidiol

A Phase 2 study of Alcohol Use Disorder, sponsored by University of Colorado, Denver.

Recruiting
Registry status
Phase 2
Development phase
180
Enrollment target
1
Study location

NCT05613608 is a Phase 2 study of Alcohol Use Disorder that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 180 participants, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05613608, a Phase 2 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Cannabidiol

Study Locations (1)

Colorado

  • University of Colorado Anschutz - Aurora

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2023-04-30
Est. Completion 2027-04
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT05613608

The ClinicalTrials.gov registry entry for NCT05613608 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (45% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05613608 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT05613608 about?

NCT05613608 is a clinical study titled "Alcohol Use Disorder and Cannabidiol". This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to re...

What is the current status of trial NCT05613608?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2023-04-30. Estimated completion is 2027-04.

What conditions does trial NCT05613608 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT05613608?

The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).

Who is sponsoring clinical trial NCT05613608?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05613608 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.